An erectile dysfunction drug could treat Alzheimer's
Key Points:
- New research suggests that AR1001, a drug containing a lower dose of mirodenafil (an erectile dysfunction treatment used in Korea), may slow cognitive decline in Alzheimer's patients by 31%, particularly in those not on standard Alzheimer's medications.
- AR1001 and sildenafil (Viagra) are both PDE5 inhibitors that improve blood flow by regulating cGMP, with potential benefits in enhancing brain blood flow and reducing Alzheimer's-related damage.
- Mirodenafil is approved for erectile dysfunction in Korea but not yet FDA approved in the US; AR1001 is currently in phase 3 clinical trials for Alzheimer's and could apply for FDA approval by 2027.
- Unlike existing Alzheimer's treatments like Donanemab and Lecanemab, which require IV infusions, AR1001 offers a convenient once-a-day oral pill option aimed at slowing disease progression in early-stage Alzheimer's patients.
- Researchers observed that AR1001 may help preserve molecules crucial for brain cell communication, supporting its potential effectiveness in slowing Alzheimer's progression and expanding treatment options.